PROM1 and cancer: As revealed in Figure 5(a), EVs derived from cancer cells significantly upregulated the ratio of CD44+ CD90+ CD133+ cells in BMSCs, while this phenomenon was reversed by EVs with downregulated miR-126 and aggravated by miR-126-overexpressed EVs.